Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ALAB
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 661 | $211.41 | $139.7K Sale | Form 4 ↗ |
| Nov 5, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 8,333 | $211.41 | $1.8M Sale | Form 4 ↗ |
| Nov 5, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 3,505 | $211.41 | $741.0K Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 32 | $276.75 | $8,856 Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 407 | $276.75 | $112.6K Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 172 | $276.75 | $47.6K Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 148 | $275.53 | $40.8K Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 1,867 | $275.53 | $514.4K Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 785 | $275.53 | $216.3K Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 429 | $274.79 | $117.9K Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 5,409 | $274.79 | $1.5M Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 2,275 | $274.79 | $625.1K Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 52 | $273.64 | $14.2K Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 650 | $273.64 | $177.9K Sale | Form 4 ↗ |
| Sep 2, 2026 | Stefan A. Dyckerhoff Director | ALAB Astera Labs, Inc. | Sale | 273 | $273.64 | $74.7K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 196 | $288.95 | $56.6K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 225 | $287.93 | $64.8K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 588 | $287.00 | $168.8K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 74 | $285.18 | $21.1K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 491 | $284.18 | $139.5K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 868 | $283.18 | $245.8K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 1,288 | $282.13 | $363.4K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 2,835 | $281.16 | $797.1K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 13,070 | $280.04 | $3.7M Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 8,179 | $279.28 | $2.3M Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 4,618 | $278.33 | $1.3M Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 568 | $277.32 | $157.5K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 892 | $288.95 | $257.7K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 1,019 | $287.93 | $293.4K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 2,677 | $286.99 | $768.3K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 340 | $285.18 | $97.0K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 2,245 | $284.17 | $638.0K Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 3,954 | $283.19 | $1.1M Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 5,870 | $282.13 | $1.7M Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 12,882 | $281.16 | $3.6M Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 59,379 | $280.04 | $16.6M Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 37,176 | $279.28 | $10.4M Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 20,991 | $278.33 | $5.8M Sale | Form 4 ↗ |
| Sep 1, 2026 | Manuel Alba Director | ALAB Astera Labs, Inc. | Sale | 2,575 | $277.32 | $714.1K Sale | Form 4 ↗ |
| Aug 17, 2026 | Sanjay Gajendra President and COO, Director | ALAB Astera Labs, Inc. | Sale | 12,608 | $333.60 | $4.2M Sale | Form 4 ↗ |
| Aug 17, 2026 | Sanjay Gajendra President and COO, Director | ALAB Astera Labs, Inc. | Sale | 6,926 | $334.23 | $2.3M Sale | Form 4 ↗ |
| Aug 17, 2026 | Sanjay Gajendra President and COO, Director | ALAB Astera Labs, Inc. | Sale | 1,782 | $335.41 | $597.7K Sale | Form 4 ↗ |
| Aug 17, 2026 | Sanjay Gajendra President and COO, Director | ALAB Astera Labs, Inc. | Sale | 2,946 | $336.65 | $991.8K Sale | Form 4 ↗ |
| Aug 17, 2026 | Sanjay Gajendra President and COO, Director | ALAB Astera Labs, Inc. | Sale | 10,438 | $337.76 | $3.5M Sale | Form 4 ↗ |
| Aug 17, 2026 | Sanjay Gajendra President and COO, Director | ALAB Astera Labs, Inc. | Sale | 7,992 | $338.58 | $2.7M Sale | Form 4 ↗ |
| Aug 17, 2026 | Sanjay Gajendra President and COO, Director | ALAB Astera Labs, Inc. | Sale | 6,484 | $339.74 | $2.2M Sale | Form 4 ↗ |
| Aug 17, 2026 | Sanjay Gajendra President and COO, Director | ALAB Astera Labs, Inc. | Sale | 2,616 | $340.58 | $891.0K Sale | Form 4 ↗ |
| Aug 17, 2026 | Sanjay Gajendra President and COO, Director | ALAB Astera Labs, Inc. | Sale | 1,610 | $341.71 | $550.2K Sale | Form 4 ↗ |
| Aug 17, 2026 | Sanjay Gajendra President and COO, Director | ALAB Astera Labs, Inc. | Sale | 5,449 | $342.95 | $1.9M Sale | Form 4 ↗ |
| Aug 17, 2026 | Sanjay Gajendra President and COO, Director | ALAB Astera Labs, Inc. | Sale | 3,713 | $343.94 | $1.3M Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:29 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances